Latest Breaking News On - Christelle huguet - Page 2 : vimarsana.com

Ipsen Pharma: Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

France generalUnited statesUnited kingdomHong kongChristelle huguetRachel reiffKris kowdleyNicolas boglerAnna gibbinsAmy wolfCarol robertsClin gastroenterol hepatolIpsen euronextIpsen pharmaceuticals incRegulatory agencyLiver institute

Ipsen s Iqirvo® receives U S FDA accelerated approval as a

Ipsen s Iqirvo® receives U S FDA accelerated approval as a
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesHong kongUnited kingdomCarol robertsAnna gibbinsRachel reiffIpsen euronextClin gastroenterol hepatolNicolas boglerAmy wolfChristelle huguetKris kowdleyEuropean medicines agencyIpsen pharmaceuticals incFibrotic liver disease consortium investigators

Ipsen, Genfit Medicine Is Cleared by FDA for Rare Liver Disorder

Ipsen, Genfit Medicine Is Cleared by FDA for Rare Liver Disorder
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Naomi kresgeFiona rutherfordChristelle huguetDrug administrationGilead sciences incGilead sciencesCymabay therapeutics

Elafibranor has significant, sustained treatment benefit in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease

United statesChristelle huguetBymonica stonehillAndrease kremerHeather bieleChristopherl bowlusUniversity hospital zurichUc davis healthLiver meeting

FDA Approves New First-Line Med for Pancreatic Cancer as Drug s Initial Developer Dissolves

Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack plans to dissolve operations but its shareholders will receive payouts from the Ipsen payment.

United kingdomChristelle huguetMerrimack pharmaceuticalsMassachusetts based merrimack pharmaceuticalsWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciencesRock healthStartup adviceStartup fundingPatient monitoring systemOtion sensors